Silence Therapeutics plc's positive results achieved from phase 1 SANRECO study using divesiran for the treatment of patients with polycythemia vera. The global polycythemia vera treatment market size ...
A strategic and financial recalibration on psychiatric drug development brings profound implications for investors, insurers, ...
Winrevair yielded significant and meaningful clinical benefits for patients with combined post- and precapillary pulmonary ...
In 2022, the combined research and development (R&D) expenditure of the U.S. pharmaceutical industry consisted of more than $100 billion. While this is a significantly expansive market, approximately ...
Alixorexton’s Phase II performance sets it up for late-stage success, according to analysts at Truist Securities. Alkermes ...
SAN DIEGO--(BUSINESS WIRE)--Iambic Therapeutics, a clinical-stage biotechnology company developing novel therapeutics using its unique AI-driven discovery platform, today announced Enchant™, a ...
In my previous article, I discussed how AI is rapidly transforming the drug discovery process, significantly accelerating timelines and reducing costs. However, while AI's potential in this domain is ...
Altasciences, a fully integrated drug development solution company, and VoxCell BioInnovation (“VoxCell”), a leader in 3D bioprinting and human-like tissue modeling, are pleased to announce a ...
Denmark's Zealand Pharma said on Thursday it has paused the development of an early-stage obesity drug candidate as it shifts focus to more promising programs. The drug dapiglutide, a GLP-1/GLP-2 ...
June 17 (Reuters) - Aerovate Therapeutics (AVTE.O), opens new tab said on Monday it was scrapping the late-stage development of its lead experimental drug to treat a rare lung condition after it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback